These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 11064911)
41. The role of PSA in secondary screening of the same population. Schröder FH Arch Ital Urol Androl; 2006 Dec; 78(4):147-8. PubMed ID: 17269619 [TBL] [Abstract][Full Text] [Related]
43. Lectin and serum-PSA interaction as a screening test for prostate cancer. Basu PS; Majhi R; Batabyal SK Clin Biochem; 2003 Jul; 36(5):373-6. PubMed ID: 12849869 [TBL] [Abstract][Full Text] [Related]
44. Adding age and genetic risk to PSA test could improve screening for prostate cancer. Kmietowicz Z BMJ; 2012 Nov; 345():e7467. PubMed ID: 23131672 [No Abstract] [Full Text] [Related]
45. Abandoning isolated free PSA screenings for more comprehensive cardiovascular and cancer screening and education. Moyad MA Urol Nurs; 2005 Apr; 25(2):137-41. PubMed ID: 15900986 [TBL] [Abstract][Full Text] [Related]
46. [The investigation of age-specific PSA reference range as the cut-off values in the mass screening for prostatic cancer]. Nakanishi H; Nakao M; Nomoto T; Miki T; Nakagawa S; Kitamura K; Watanabe H Nihon Hinyokika Gakkai Zasshi; 1999 Nov; 90(11):853-8. PubMed ID: 10598449 [TBL] [Abstract][Full Text] [Related]
47. Clinical usefulness of percentage of free serum prostate specific antigen. Vogl M; Müller MM; Höltl W Clin Chim Acta; 1997 Feb; 258(1):79-90. PubMed ID: 9049445 [TBL] [Abstract][Full Text] [Related]
48. Prostate-specific antigen (PSA) as a possible biomarker in non-prostatic cancer: A review. Pérez-Ibave DC; Burciaga-Flores CH; Elizondo-Riojas MÁ Cancer Epidemiol; 2018 Jun; 54():48-55. PubMed ID: 29579692 [TBL] [Abstract][Full Text] [Related]
49. [Which is the most appropriate diagnostic algorithm for prostate cancer screening?]. Allepuz Losa C; Borque Fernando A; Rioja Sanz LA Actas Urol Esp; 2005 May; 29(5):465-72. PubMed ID: 16013791 [TBL] [Abstract][Full Text] [Related]
50. [Current role of PSA and other markers in the diagnosis of prostate cancer]. Gómez Veiga F; Ponce Reixa J; Barbagelata López A; Fernández Rosado E; Gonzaĺez Martiń M Arch Esp Urol; 2006 Dec; 59(10):1069-82. PubMed ID: 17283720 [TBL] [Abstract][Full Text] [Related]
51. PSA: an update. Schulman C Arch Ital Urol Androl; 2006 Dec; 78(4):161-2. PubMed ID: 17269624 [TBL] [Abstract][Full Text] [Related]
52. [Evaluation of endorectal ultrasonography in the diagnosis of prostatic cancer using a high-frequency sectorial intracavitary probe]. Devonec M; Codas H; Provensal B; Chapelon JY; Dubernard JM; Cathignol D Ann Urol (Paris); 1987; 21(1):17-22. PubMed ID: 3551788 [TBL] [Abstract][Full Text] [Related]
53. Emerging PSA-based tests to improve screening. Bryant RJ; Lilja H Urol Clin North Am; 2014 May; 41(2):267-76. PubMed ID: 24725489 [TBL] [Abstract][Full Text] [Related]
54. Cut-off value for PSA: do we need a change? Singh JC J Postgrad Med; 2009; 55(2):150-1. PubMed ID: 19550066 [No Abstract] [Full Text] [Related]
55. Can PSA Reflex Algorithm be a valid alternative to other PSA-based prostate cancer screening strategies? Caldarelli G; Troiano G; Rosadini D; Nante N Ann Ig; 2017; 29(3):218-222. PubMed ID: 28383613 [TBL] [Abstract][Full Text] [Related]
58. [Screening for prostate cancer: arguments "against"]. Perrin P Ann Urol (Paris); 2006 Apr; 40(2):101-5. PubMed ID: 16709008 [TBL] [Abstract][Full Text] [Related]
59. PSA assay of dried blood samples from the ear lobe on a filter paper with special reference to prostatic mass screening. Watanabe H; Ohe H; Saitoh M; Kojima M; Tanaka T; Ito S Prostate; 1995 Aug; 27(2):90-4. PubMed ID: 7543671 [TBL] [Abstract][Full Text] [Related]
60. [Screening for prostate cancer by measuring PSA level: divergent recommendations, medico- legal uncertainty]. Fiquet JM; Delage P; Ruffie S Rev Prat; 2021 Jun; 71(6):605-611. PubMed ID: 34553546 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]